Chronic Kidney Disease (CKD): Symptoms, Treatment, Monitoring & Red Flags
KDIGO G/A ladders, prescribing cautions tied to filtration, anemia–potassium interplay, dialysis transition triggers, distinguishing AKI overlays.
Featured snippet
Chronic kidney disease (CKD) means kidney damage or filtration loss persisting roughly three months or more—shown by lowered eGFR, albuminuria, imaging, biopsy, or other structural cues. Nurses operationalise KDIGO G/A strata to pace labs, supervise RAAS inhibitors and SGLT2 pathways, escalate hyperkalemia choreography, steward antibiotics, anaemia irons, dialysis access timelines, transplant education, palliative transitions, and vigilant discrimination of acute overlays.
Clinical snapshot: Think chronicity markers first, cardiometabolic control second, poisonous polypharmacy third—then escalate any sprinting creatinine as possible AKI until disproven.
- Stage CKD with paired G-category filtration loss and persistent A-category albuminuria—not from a solitary hospital creatinine glitch.
- Leverage renin–angiotensin modulation (such as ACE inhibitors illustrated by our lisinopril monograph posture) strictly within potassium/creatinine guardrails dictated by prescribing teams.
- Serial potassium assays belong on the same escalation mental model as opioids when combining MRAs plus RAAS inhibition across advanced filtration loss.
- Drug concentration risk climbs insidiously—narrow therapeutic agents like digoxin demand pacing clues, gastrointestinal bleeding surveillance, ophthalmic disturbances reported early.
- Any sudden creatinine inflection mandates superimposed acute kidney injury scrutiny even when chronic labels already populate the demographics banner.
⚡ Quick Facts
💡 Clinical Pearl
Creatinine camouflage hides falling GFR in sarcopenia. Frail elders may cling to serum creatinine “within range” despite meaningful G-category decline—trend cystatin-C workflows where policy allows rather than reassurance off one lab band.
📋 Contents
What is Chronic Kidney Disease?
Chronic kidney disease (CKD) is abnormalities of kidney structure or function that persist for roughly three months or longer, evidenced by reductions in estimated glomerular filtration rate (eGFR) and/or markers such as elevated albumin on urinalysis or urinary albumin excretion assays. Nurses interpret CKD primarily as longitudinal risk for cardiovascular collapse, anemia, brittle electrolytes, and superimposed acute kidney injury spikes rather than a single creatinine screenshot.
Most ward encounters reflect arterionephrosclerosis compounded by cardiometabolic disease: type 2 diabetes– and hypertension-related glomerulosclerosis coexist with endothelial stiffness. Obstructive uropathy, recurrent pyelonephritis, nephrocalcinosis from recurrent kidney stones, toxin exposure, autoimmune glomerular processes, polycystic genotypes (not catalogued here—follow local pathology), hepatorenal physiology partnerships, or heart failure-driven venous congestion all colour nursing surveillance differently. Severity staging frames monitoring cadence, referral triggers, dialysis planning, prescribing ceilings, anaemia workflows, vaccination schedules, transplant candidacy counselling, communications with pharmacies, and escalation expectations—notably when an acute deterioration masquerades as “just CKD creeping.”
KDIGO G stages & albuminuria (A) categories
Use two axes together: graded fall in filtration (G stages from eGFR against stable assays over ≥90 days absent competing AKI physiology) plus persistent albumin exposure via urinary albumin–creatinine ratio patterns often grouped A1/A2/A3. Heat-map style risk tables appear in KDIGO and NICE summaries—combinations near “red” dictate aggressive renoprotection, tighter blood pressure ladders, multidisciplinary diabetes review, dialysis access contingency planning across some geographies.
| G stage | Approximate sustained eGFR (mL/min/1.73 m²) | Implications triggering nursing vigilance |
|---|---|---|
| G1 | ≥90 with kidney damage marker | May look “healthy” numeric eGFR; albuminuria or structural imaging still designates CKD—track cardiovascular coaching, medicine toxicities. |
| G2 | 60–89 | Repeat confirmation before labelling lifelong CKD whenever acute illness overlaps; escalate if trajectory falls quickly. |
| G3a | 45–59 | Primary-care shared care common; optimise BP, minimise nephrotoxins. |
| G3b | 30–44 | Referral thresholds often land here with proteinuria markers; anemia workups intensify. |
| G4 | 15–29 | Prepare patients psychologically/educationally for kidney replacement modality selection; phosphorus, calcium, hematology labs cycle faster. |
| G5 | <15 or on dialysis | Strict fluid/solute nursing plus complex medication reconciliation coordinated with dialysis unit. |
On a small screen, swipe or scroll sideways to see the full table.
A stages (persistently abnormal albuminuria)
| A stage | Typical ACR shorthand | Operational meaning |
|---|---|---|
| A1 | <30 mg/g (“normal–mild”) | Renoprotection still warranted when diabetic or cardiometabolic; not “no CKD”. Use microalbuminuria-style screening workflows per policy. |
| A2 | 30–300 mg/g | Moderately elevated albuminuria—ACEi/ARB and SGLT2 conversations escalate per guideline layers. |
| A3 | >300 mg/g | High albuminuria with rapid referral expectations in many locales; biopsy or immunology cascades initiated by clinicians. |
On a small screen, swipe or scroll sideways to see the full table.
Units (mg/g vs mg/mmol) differ globally—never interpret ACR thresholds from memory alone. Children, pregnancy, amputees, extremes of muscle mass, liver failure, cystatin-C programmes, cystic kidneys, solitary kidneys, AKI overlays, acute heart failure congestion, iodinated contrasts, dehydration, NSAID boluses—all distort electrolyte / BUN–creatinine couplets transiently.
Even with known CKD charts, escalate when acute collapse patterns emerge—you may be witnessing AKI atop CKD versus accelerated CKD alone:
- Altered cognition with malignant hypertension, pounding headache, seizures, florid papilloedema (hypertensive emergency spectrum).
- Refractory hyperkalaemia, peaked T waves progressing to sine-wave morphology, peri-arrest physiology.
- Severe uraemic pericardial friction rub plus chest pain, hypoxia uncontrollable outside critical care escalation.
- Fluid overload pulmonary oedema refractory despite diuretics & not compensable on ward suction/CPAP escalation limits.
Immediate actions: Call senior medical/critical-care pathway per policy, continuous telemetry when potassium threat looms, obtain stat venous blood gas pairing with repeat creatinine deltas, withhold nephrotoxins verbally + electronically, cease oral potassium supplementation or accidental salt substitutes quietly hiding K+; prepare dialysis access conversations without falsely reassuring anxious relatives that “baseline CKD always explains deterioration.”
Symptoms
Stages G1–early G3 often produce zero patient-reported symptoms—the disease lives inside analytics. When patients finally voice symptoms, severity may already encroach G4–G5 or reflect superimposed instability: screen for fatigue overshadowing sleep, nausea with ammonia taste, uncontrolled pruritus scratching excoriations, restless legs, gait slowing from uremic neuropathy, unexplained bleeding, or easy bruising reflecting platelet dysfunction. Volume expansion shows dependent edema or orthopnoea mirroring echocardiogram-proven diastolic stiffness; diuretic dosing must never be titrated by nursing alone when advanced CKD nears dialysis.
Typical manifestations when they appear
- Progressive anemia with pallor, tachycardia, angina equivalence in diabetics—coordinate with iron saturation policies before assuming “CKD anaemia only needs ESA shots.”
- Normocytic anaemia compounded by covert GI bleed or myelosuppression—chart occult stools when hemoglobin plummets abruptly.
- Hypertensive surges alternating with dizzy crashes when RAS blockade and diuretics battle autonomic neuropathy concurrently.
Atypical or confounding narratives
- Older malnourished adults mask creatinine rise because muscle-derived creatinine production falls—“stable creatinine despite dropping GFR biochemically disguised”. Always compare eGFR trend lines.
- Heart failure overlaps blur symptoms; loop diuresis may hide fluid retention until precipitously failing.
- Diabetics perceive neuropathic feet pain rather than ischaemic rest pain—coordinate podiatry & perfusion cues.
Causes and Risk Factors
Structural drivers include hypertensive arterionephrosclerosis, diabetic nodular disease, histories of chronic glomerular inflammation, developmental cystic kidneys, reflux-atrophic patterns, solitary kidneys, renovascular stenoses, and haemoglobinopathies—all demand documentation accuracy when nursing hands off multidisciplinary teams beyond nephrology. Modifiable amplifiers include reckless non-prescription NSAID reliance (ibuprofen class), dehydration from poorly titrated diabetic ketosis management, lithogenic dehydration, and misunderstandings about phosphate binders or diet sodium loads.
Non-modifiable or partially modifiable substrates
- Familial CKD genotype clusters invisible on admission unless asked—document pedigree hints before contrast exposure.
- Autoimmune serologies positive without recent biopsy—assume ongoing immune activity until specialist states otherwise.
- Longstanding cardiac disease with cardiorenal syndrome physiology—coordinate afterload reduction without precipitating oliguria blindly.
Modifiable drivers needing nursing advocacy
- Salt supplementation cocktails in heart failure exacerbations juxtaposed RAS inhibitors escalate hyperkalemia synergy—flag early.
- Unsupervised OTC analgesics, lithium, tacrolimus, calcineurin inhibitors, proton-pump inhibitor overuse anecdotes—medicine histories must mention non-prescribed powders.
- Missed dialysis sessions or catheter dressing breaches increase bacteremia avalanche—education & documentation matter.
How is it Diagnosed?
Clinical assessment
Screen risk registers (diabetes, hypertension, established cardiovascular disease, donor nephrectomy history, familial kidney failure) per local primary-care contracts. Measure blood pressure with correct cuff sizing; listen for pericardial rub; examine for fluid overload and wasting; document medication possession for RAAS blockers, SGLT2 inhibitors, mineralocorticoid antagonists, trimethoprim, heparin, calcineurin inhibitors. Ask about thirst shifts, nocturia evolution, stone symptoms, haematuria, foamy urine, pregnancy, contrast timing, diarrhoea threatening prerenal physiology.
Laboratory investigations
- Two eGFR estimations ≥90 days apart below 60 mL/min/1.73 m² OR persistent albuminuria / other damage markers define CKD in most schemes—never label new lifelong CKD on a single inpatient draw.
- Compare creatinine with blood urea nitrogen ratios only as adjuncts (GI bleed, steroid catabolism skew ureagenesis).
- Repeat urinalysis for blood cells, casts, glycosuria surrogate clues alongside formal albuminuria testing.
- Track electrolytes when escalating diuretics, MRAs, or RAAS inhibition—coordinate vitals timing with specimen collection.
- Promote meticulous venipuncture hygiene to dodge haemolysis artefact falsely elevating potassium.
Imaging
Ultrasound delineates obstruction, echogenic kidneys, asymmetric sizes. Deploy echocardiography when LV dysfunction confounds congestion versus CKD oliguria narratives. Respect contrast committees—communication beats silent creatinine shocks.
Diagnostic criteria / scoring used in practice
KDIGO aligns G-stage filtration loss with persistent A-stage albuminuria for combined risk signalling; NG203 layers UK monitoring densities. Always exclude superimposed AKI physiology before declaring sluggish progression.
Differential Diagnoses
Creatinine perturbations oscillate among chronic sluggish decline, reversible prerenal states, tubular injury pigment syndromes, obstructive calamities—frame tempo first.
| Entity | Helpful clues | Actions |
|---|---|---|
| AKI on CKD | Fast rise with trigger (sepsis, bleeding, toxin) | AKI bundle + nephrology per stage |
| Haemodynamic prerenal | Orthostasis, gastrointestinal losses | Volume strategy per senior—not nursing solo boluses |
| Intrinsic GN / AIN flare | Active sediment, eosinophilia, immune drug timeline | Urinalysis microscopy escalate; steroid plans specialist-only |
| Obstruction | Hydronephrosis imaging, tumour, BPH physiology | Drainage pathway before blaming CKD slump |
| Lab confounders | Tolbutamide interfering creatinine assays rare but taught; extremes of bilirubin | Repeat via clean draw; question interference |
On a small screen, swipe or scroll sideways to see the full table.
Clinical decision flow
- Verify chronic kidney signature: Pair structural or laboratory persistence across ≥90 days unless biopsy-proven instantaneous damage diagnoses.
- Grade combined risk: Overlay G+A heat map plus diabetes/frailty stratifiers translating to monitoring ladders from NICE-style tables locally adopted.
- Implement renocardiovascular pharmacology: Titrate guideline-indicated therapies—observe mandatory labs after upward titration waves.
- Enforce prescribing hygiene: Renal dosing, sick-day counselling for metformin, contrast mitigation lists, intercepting over-the-counter NSAID purchases lacking pharmacy review.
- Survey complications calendars: Anaemia irons, KT/V analogues inpatient transfer contexts, brittle bone adjunct symptom screens.
- Forecast transitions honestly: G4 counselling seeds realistic modality expectations; escalate psychosocial collateral early.
Treatment Options
Renoprotection & blood pressure scaffolding
- ACE inhibitors / ARBs (typified by ramipril) remain backbone therapy for proteinuric states when pregnancy status, bilateral renovascular suspicion, intolerance, potassium ceiling allow—observe creatinine bumps expected ≤30% early window per policy narratives.
- Empagliflozin and sister SGLT2 molecules surface in KDIGO/NICE-aligned pathways for cardio-renal indications—coach volume-aware patients about ketone vigilance episodes.
- Loop agents (furosemide) manage cardiorenal congestion; monitor magnesium alongside potassium declines.
- Selected congestive cohorts tolerate spironolactone synergy with RAS blockade yet skyrocket hyperkalaemia telemetry—paired nursing vitals paramount.
Anaemia & erythropoietic adjuncts
- Intravenous iron or oral surrogates precede escalating erythropoietin dosing per CKD anemia programmes—know institutional transfusion sparing thresholds versus symptomatic exemptions.
Dialysis & transplantation interfaces
Haemodialysis, peritoneal dialysis, transplantation, symptom-led conservative renal care hinge on multidisciplinary consensus when GFR approximates symptom burden arcs. Nurses operationalise dialysis schedules, phosphate binder dosing intervals, vascular access sterile technique, transplant immunosuppressive safety teaching—beyond page scope individually but escalation triggers stay identical.
Special populations
Paediatric dosing worlds differ; pregnancy forbids ACEi/ARB; geriatrics suffer orthostatic BP swings; indigenous or marginalised cohorts endure access inequities—document advocacy referrals when dialysis geography blocks attendance.
Clinical Practice Considerations
- Monitoring cadence: Align repeat electrolyte panels with G-stage tables (NICE tiers often quote 12-month vs 6-month cadences for stable low-risk strata ramping tighter as heat-map colour reddens)—always defer to institutional grids.
- Prescribing choreography: Document creatinine deltas after RAS titrations greater than pragmatic thresholds mandated locally; escalate potassium >5.0 trending persistently paired with electrocardiographic surveillance per protocol.
- Transitions of care: Discharge summaries must carry latest ACR magnitude, dialysis access type, fistula avoidance with blood draws downstream, pharmacist brown-bag inventories.
- Population vulnerabilities: Indigenous, rural geography, incarceration, dialysis transportation poverty—surface social determinants provoking missed laboratory surveillance.
- Referral etiquette: Fast-track unexplained microscopic haematuria with declining GFR, malignant hypertension arcs, dialysis candidacy ambiguity—don’t bottleneck behind routine clinic slots.
Possible Complications
- Refractory hyperkalaemic cardiotoxic cascades—even while ambulatory fistula-dependent individuals wait ride-shares.
- Uraemic bleeding diatheses masquerading as anticoagulant overdosing.
- Accelerated vascular calcifications manifesting limb ischaemia, steal syndromes, calciphylaxis rare but devastating snapshots.
- Malnutrition inflammation aetiology cohort wasting despite adequate calorie counts.
- Pericarditis signalling emergent dialysis needs.
Prevention
Case-finding in diabetes and hypertension ecosystems using paired urinary albumin–creatinine screening plus eGFR trending prevents silent structural injury progression. Steward iodinated contrasts, antimicrobial durations, antifungals, tumour lysis preparedness. Immunise influenza, hepatitis B milestones per CKD strata. Coach smoking cessation verbally even when cardiologists already reiterated—frequency amplifies behavioural adherence.
Prognosis and Outlook
Trajectory hinges on genotype, phenotype, socioeconomic adherence, dialysis modality quality, transplantation luck, fistula maturity success. Conversations acknowledging uncertainty outperform falsely precise timelines; emphasise reversible accelerators (recurrent urinary stone disease segments, uncontrolled glycaemia).
In Clinical Practice…
- Hearing “I always feel tired” juxtaposed plummeting haemoglobin—don’t autopilot erythropoietin escalation without iron stewardship conversations.
- Arm vein preservation diplomacy when patients still produce urine pre-fistula—draw blood from dorsal veins where policy supports.
- Translate nephrology “sick day” directives into plain language laminated cards patients pocket during cruise vacations.
Bedside monitoring checklist
- Weight & I&Os: Compare against dry-weight targets dialysis teams publish; escalate unexplained nightly gains exceeding agreed tolerance.
- Blood pressure pattern: Orthostatics when titrating vasodilators; document positions consistently.
- Skin & access: Fistula thrill vs bruit changes, dialysis catheter exit erythema, subcutaneous edema signalling access outflow obstruction.
- Respiratory reserve: orthopnea sneaking upward often flags fluid choreography failure.
- Glucose interplay: Hypoglycaemia risk magnification when renally cleared insulin secretagogue doses linger unchecked.
When to Seek Emergency Care
- Airway-threatening pulmonary oedema refractory high-flow oxygen escalation.
- Symptomatic bradycardia or broad complex tachycardia tied to malignant hyperkalaemia ladders.
- Convulsions, rapid neurological decline bridging uraemic encephalopathy suspicions.
- Haemorrhagic shock interplay with dialysis anticoagulation mistakes.
Deterioration & escalation
Invoke rapid-response or nephrology hotlines whenever mental status contracts against rising azotaemia, potassium refuses downtrend despite protocolised shifts, oliguria persists against diuretics + dialysis contingency minutes away, uncompensated metabolic acidosis deepens sequentially on venous gases, unexplained bleeding saturates dialysis circuit repeatedly. Narrate escalation timestamps legibly defending medicolegal clarity.
NCLEX practice questions
These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and a compact cloze on the topic of CKD staging (eGFR + ACR / KDIGO heat-map), ACE-I / ARB + SGLT2 inhibitor stewardship, anaemia / mineral-bone-disease bundles and the hyperkalaemia / uraemic-emergency / dialysis red flags.
Unfolding case (Questions 1–3): Mr. A., 64, with type-2 diabetes, hypertension and CKD G3b A3 (eGFR 38, ACR 80 mg/mmol), presents to the renal clinic with progressive fatigue and ankle swelling. BP 162/96, K⁺ 5.6, HCO₃ 18, Hb 96, ferritin 60, vitamin D low, PTH raised, urine ACR rising. He is on ramipril, atorvastatin, metformin, gliclazide and ibuprofen for back pain.
Answer key & rationale
When does KDIGO say CKD is present?
Kidney abnormalities lasting at least ~3 months—including estimated GFR persistently below 60 mL/min/1.73 m² using appropriate equations/labs AND/OR markers of kidney damage such as albuminuria, urinary sediment anomalies, biopsy or imaging evidence—establish CKD. Acute deviations need comparison with AKI workflows.
How often should eGFR repeat in unstable outpatients?
Many programmes recheck renal function sooner after new medicines, dehydration, gastrointestinal losses, bleeding, or peri-contrast exposures—typically within days to ~2 weeks depending on baseline stage and guideline-driven risk. Faster cadence accompanies rising creatinine, hyperkalemia prompts, pregnancy, or dialysis planning.
Are ACE inhibitors and ARBs incompatible with CKD?
They are cornerstone renoprotective options for proteinuric diabetic and many nondiabetes CKD cohorts within tolerable electrolyte safety but require clinician-led titration, potassium monitoring after starts or dose climbs, caution with dual RAAS inhibition, acute intercurrent illness bundles, pregnancy contraindications per local policy, and peri-contrast stewardship.
When should NSAIDs alarm bells ring?
Older adults combining loop diuretics, ACE inhibitor/ARB, and NSAID (‘triple whammy’), volume depletion, septic episodes, obstructive urinary symptoms, baseline eGFR <60, or escalating creatinine—all warrant escalation before repeat doses. Nurses should flag ingestion when charting—not assume pharmacy alone audits OTC use.
What hemoglobin thresholds trigger specialist anaemia pathways?
Institutions stratify dialysis versus nondialysis thresholds and iron-repletion prerequisites before escalating erythropoiesis-stimulating therapies. Persistently trending below local hemoglobin action lines, symptomatic anemia with HF, falling iron indices, or reticulocyte mismatch mandates charted escalation rather than lone blood transfusion rituals.
How do I separate CKD slump from AKI catastrophe?
AKI hunts rapid creatinine deltas, oliguria timelines, toxin exposure narratives, obstruction signs, septic physiology, hypotension—use dedicated AKI grids. CKD slump still demands senior review yet might track slower deterioration with planned medications adjustment; unexplained brisk falls behave like renal emergencies until clarified.
When is nephrology referral usually indicated?
Accelerating progression, unexplained microscopic hematuria with proteinuria, electrolyte catastrophes, refractory hypertension, anemia management complexity, transplantation candidacy counselling, dialysis access anticipation, recurrent stone disease with tubular disorders, biopsy suspicions—all vary by locality but uniformly exceed solitary nursing monitoring.
What diet teaching points persist at hospital bedside?
Nutrition prescribing is dialysis-stage specific and requires dietitian overlays; bedside nurses realistically emphasise phosphate additive awareness cues, adherence to phosphate binder timing when prescribed fluid restriction communication, carbohydrate consistency for insulinised diabetes, avoidance of covert sodium loads, translating nephrology ‘sick-day’ lists verbally to families during acute admissions.
- National Institute for Health and Care Excellence (NICE). Chronic kidney disease: assessment and management (NG203).https://www.nice.org.uk/guidance/ng203
- NICE. Chronic kidney disease quality standard (QS167).https://www.nice.org.uk/guidance/qs167
- Kidney Disease: Improving Global Outcomes (KDIGO). CKD Evaluation and Management guideline suite.https://kdigo.org/guidelines/ckd-evaluation-and-management/
- KDIGO. CKD–Mineral and Bone Disorder (CKD-MBD) guideline suite.https://kdigo.org/guidelines/ckd-mbd/
- Stevens PE, Levin A; KDIGO CKD Guideline Development Work Group. Evaluation and management of chronic kidney disease: synopsis of the KDIGO 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825-830.https://pubmed.ncbi.nlm.nih.gov/23732715/
- Levin A, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4):684-701.https://pubmed.ncbi.nlm.nih.gov/38519239/
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Chronic kidney disease overview.https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd
- NHS. Chronic kidney disease overview (symptoms, diagnosis, living with CKD).https://www.nhs.uk/conditions/kidney-disease/
- Centers for Disease Control and Prevention (CDC). Chronic kidney disease basics.https://www.cdc.gov/kidney-disease/about/
- World Health Organization (WHO). Kidney disease fact sheet.https://www.who.int/news-room/fact-sheets/detail/kidney-disease
- National Kidney Foundation (NKF). Professionals hub (KDOQI guideline context and practice resources).https://www.kidney.org/professionals
- StatPearls [Internet]. Chronic kidney disease — NCBI Bookshelf.https://www.ncbi.nlm.nih.gov/books/NBK535404/
- MedlinePlus (NLM). Chronic kidney disease — patient-facing overview.https://medlineplus.gov/chronickidneydisease.html